drug · small molecule
icosapent ethyl
Marketedupdated 6mo agoby KD Pharma Group SA🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval94 co-mentions · 47 sources
- drugELELYSO36 co-mentions · 18 sources
- drugtaliglucerase alfa36 co-mentions · 18 sources
- drugefgartigimod alfa26 co-mentions · 13 sources
- drugFOLLISTIM AQ24 co-mentions · 12 sources
- companyOrganon USA LLC12 co-mentions · 12 sources
- drugfollitropin alfa12 co-mentions · 12 sources
- drugfollitropin beta12 co-mentions · 12 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 6 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying icosapent ethyl
- phase3FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- phase3A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- phase2NAI Plus Standard of Care Compared To SOC Alone Plus Standard of Care in Critically Ill Adults With Sepsis
- —A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)
- phase3A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- phase4Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
- phase3A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- phase3An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 31, 2027
189 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (122)
- Jun 28, 2033method-of-use (U-2701)US 10278935
- Jun 28, 2033method-of-use (U-2701)US 10278935
- Jun 28, 2033method-of-use (U-2702)US 10278936
- Jun 28, 2033method-of-use (U-2702)US 10278936
- Jun 28, 2033method-of-use (U-2703)US 10278937
- Jun 28, 2033method-of-use (U-2703)US 10278937
- Jun 28, 2033method-of-use (U-2704)US 10383840
- Jun 28, 2033method-of-use (U-2704)US 10383840
- Jun 28, 2033method-of-use (U-2743)US 10555924
- Jun 28, 2033method-of-use (U-2743)US 10555924
- Jun 28, 2033method-of-use (U-2744)US 10555925
- Jun 28, 2033method-of-use (U-2744)US 10555925
- Jun 28, 2033method-of-use (U-2756)US 10568861
- Jun 28, 2033method-of-use (U-2756)US 10568861
- Jun 28, 2033method-of-use (U-2762)US 10576054
- Jun 28, 2033method-of-use (U-2762)US 10576054
- Jun 28, 2033method-of-use (U-2841)US 10668042
- Jun 28, 2033method-of-use (U-2841)US 10668042
- Jun 28, 2033method-of-use (U-2960)US 10786478
- Jun 28, 2033method-of-use (U-2960)US 10786478
- Jun 28, 2033method-of-use (U-2962)US 10792270
- Jun 28, 2033method-of-use (U-2962)US 10792270
- Jun 28, 2033method-of-use (U-3053)US 10894028
- Jun 28, 2033method-of-use (U-3053)US 10894028
- Jun 28, 2033method-of-use (U-3126)US 11000499
- Jun 28, 2033method-of-use (U-3126)US 11000499
- Jun 28, 2033method-of-use (U-3221)US 11116742
- Jun 28, 2033method-of-use (U-3221)US 11116742
- Jun 28, 2033method-of-use (U-3358)US 11298333
- Jun 28, 2033method-of-use (U-3358)US 11298333
- Jun 28, 2033method-of-use (U-2841)US 11369582
- Jun 28, 2033method-of-use (U-2841)US 11369582
- Jun 28, 2033method-of-use (U-2696)US 9603826
- Jun 28, 2033method-of-use (U-2696)US 9603826
- Jun 28, 2033method-of-use (U-2697)US 9610272
- Jun 28, 2033method-of-use (U-2697)US 9610272
- Jun 28, 2033method-of-use (U-2698)US 9623001
- Jun 28, 2033method-of-use (U-2698)US 9623001
- Jun 28, 2033method-of-use (U-2697)US 9693984
- Jun 28, 2033method-of-use (U-2697)US 9693984
- Jun 28, 2033method-of-use (U-2696)US 9693985
- Jun 28, 2033method-of-use (U-2696)US 9693985
- Jun 28, 2033method-of-use (U-2698)US 9693986
- Jun 28, 2033method-of-use (U-2698)US 9693986
- Jun 28, 2033method-of-use (U-2699)US 9918954
- Jun 28, 2033method-of-use (U-2699)US 9918954
- Jun 15, 2030method-of-use (U-2688)US 108427683.6y
- Jun 15, 2030method-of-use (U-2688)US 108427683.6y
- Jun 15, 2030method-of-use (U-2688)US 84100863.6y
- Jun 15, 2030method-of-use (U-2688)US 84100863.6y
- Jun 15, 2030method-of-use (U-2690)US 84554723.6y
- Jun 15, 2030method-of-use (U-2694)US 86692453.6y
- Jun 15, 2030method-of-use (U-2694)US 86692453.6y
- Jun 15, 2030method-of-use (U-2690)US 87100413.6y
- Jun 15, 2030method-of-use (U-2690)US 87100413.6y
- Apr 29, 2030method-of-use (U-2690)US 100105173.4y
- Apr 29, 2030method-of-use (U-2690)US 100105173.4y
- Apr 29, 2030method-of-use (U-2700)US 102652873.4y
- Apr 29, 2030method-of-use (U-2700)US 102652873.4y
- Apr 29, 2030method-of-use (U-2961)US 107922673.4y
- Apr 29, 2030method-of-use (U-2961)US 107922673.4y
- Apr 29, 2030method-of-use (U-2997)US 108427663.4y
- Apr 29, 2030method-of-use (U-2997)US 108427663.4y
- Apr 29, 2030method-of-use (U-3052)US 108816323.4y
- Apr 29, 2030method-of-use (U-3052)US 108816323.4y
- Apr 29, 2030method-of-use (U-3209)US 111034773.4y
- Apr 29, 2030method-of-use (U-3209)US 111034773.4y
- Apr 29, 2030method-of-use (U-3240)US 111545263.4y
- Apr 29, 2030method-of-use (U-3240)US 111545263.4y
- Apr 29, 2030method-of-use (U-3292)US 112135043.4y
- Apr 29, 2030method-of-use (U-3292)US 112135043.4y
- Apr 29, 2030method-of-use (U-3669)US 117175043.4y
- Apr 29, 2030method-of-use (U-3669)US 117175043.4y
- Apr 29, 2030formulationUS 82985543.4y
- Apr 29, 2030formulationUS 82985543.4y
- Apr 29, 2030method-of-use (U-1287)US 84450033.4y
- Apr 29, 2030method-of-use (U-1287)US 84450033.4y
- Apr 29, 2030method-of-use (U-1287)US 84450133.4y
- Apr 29, 2030method-of-use (U-1287)US 84450133.4y
- Apr 29, 2030method-of-use (U-2689)US 84549943.4y
- Apr 29, 2030method-of-use (U-2689)US 84549943.4y
- Apr 29, 2030method-of-use (U-1287)US 85012253.4y
- Apr 29, 2030method-of-use (U-1287)US 85012253.4y
- Apr 29, 2030method-of-use (U-1287)US 85515213.4y
- Apr 29, 2030method-of-use (U-1287)US 85515213.4y
- Apr 29, 2030method-of-use (U-1287)US 85636083.4y
- Apr 29, 2030method-of-use (U-1287)US 85636083.4y
- Apr 29, 2030method-of-use (U-2691)US 86175933.4y
- Apr 29, 2030method-of-use (U-2691)US 86175933.4y
- Apr 29, 2030method-of-use (U-1287)US 86175943.4y
- Apr 29, 2030method-of-use (U-1287)US 86175943.4y
- Apr 29, 2030method-of-use (U-2689)US 86181663.4y
- Apr 29, 2030method-of-use (U-2692)US 86234063.4y
- Apr 29, 2030method-of-use (U-1478)US 86234063.4y
- Apr 29, 2030method-of-use (U-2693)US 86420773.4y
- Apr 29, 2030method-of-use (U-2693)US 86420773.4y
- Apr 29, 2030method-of-use (U-2689)US 86918713.4y
- Apr 29, 2030method-of-use (U-2689)US 86918713.4y
- Apr 29, 2030method-of-use (U-2691)US 87031853.4y
- Apr 29, 2030method-of-use (U-2691)US 87031853.4y
- Apr 29, 2030method-of-use (U-2689)US 87094753.4y
- Apr 29, 2030method-of-use (U-2689)US 87094753.4y
- Feb 9, 2030method-of-use (U-4105)US 121717383.2y
- Feb 9, 2030method-of-use (U-4105)US 121717383.2y
- Feb 9, 2030method-of-use (U-1287)US 83994463.2y
- Feb 9, 2030method-of-use (U-1287)US 84153353.2y
- Feb 9, 2030method-of-use (U-1287)US 84153353.2y
- Feb 9, 2030method-of-use (U-1287)US 84263993.2y
- Feb 9, 2030method-of-use (U-1287)US 84263993.2y
- Feb 9, 2030method-of-use (U-1287)US 84315603.2y
- Feb 9, 2030method-of-use (U-1287)US 85189293.2y
- Feb 9, 2030method-of-use (U-1287)US 85189293.2y
- Feb 9, 2030method-of-use (U-1287)US 85246983.2y
- Feb 9, 2030method-of-use (U-1287)US 85246983.2y
- Feb 9, 2030method-of-use (U-1287)US 85463723.2y
- Feb 9, 2030method-of-use (U-1287)US 85463723.2y
- Feb 9, 2030method-of-use (U-2695)US 86801443.2y
- Feb 9, 2030method-of-use (U-2695)US 86801443.2y
- Sep 25, 2027method-of-use (U-2706)US 9198892306d
- Sep 25, 2027method-of-use (U-2706)US 9198892306d
- May 31, 2027method-of-use (U-2707)US 9700537189d
- May 31, 2027method-of-use (U-2707)US 9700537189d
News(10)
- Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persist…biospace · 9d ago
- Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readoutAnalysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.biospace · 25d ago
- Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readoutAnalysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.biospace · 25d ago
- ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2Invikafusp alfa, a first-in-class dual T cell agonist, showed an objective response in various types of cancer, particularly among patients who did not respond to previous checkpoint inhibitor ther…biospace · 1mo ago
- Ambrose Healthcare inks $181M deal for former Pfizer target AM-PharmaAmbrose Healthcare has bought AM-Pharma for up to 161 million euros, inking a cut-price deal for a biotech once courted by Pfizer.fiercebiotech · 1mo ago
- FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder CancerFDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancerfda_press · 1mo ago
- No ‘Sunday scaries’: Claire Mazumdar on building Bicara—and knowing when to hand over the reinsStrange and bittersweet. That’s how Claire Mazumdar describes her plan to step down from the top spot at Bicara, a biotech she helped form, and head out on parental leave before transitioning into…biospace · 1mo ago
- Roche cuts muscle-sparing obesity drug after mid-stage disappointmentRoche’s anti-myostatin therapy emugrobart is unlikely to elicit meaningful weight loss, according to an interim mid-stage analysis, prompting the pharma to return the asset rights to its subsidiary…biospace · 1mo ago
- Kodiak skyrockets on positive study data for 2 eye drugsThe Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.biopharma_dive · 1mo ago
- Tolerance continues thymus-focused deals with $560M pact for Tanabe's clinical-stage IL-33 drugAfter vaulting into the clinic by licensing a fusion protein last month, Tolerance Bio has continued to strengthen its thymus-focused pipeline by picking up an anti-IL-33 drug from Tanabe Pharma.fiercebiotech · 1mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that